Ram Raju's questions to Protalix Biotherapeutics Inc (PLX) leadership • Q1 2025
Question
Representing H.C. Wainwright & Co., an analyst asked for confirmation on the FDA regulatory body for ProCellEx products, the potential impact of U.S. pharmaceutical tariffs on cost of goods sold, and whether partner Chiesi has discussed raising Elfabrio's U.S. list price.
Answer
Executive Dror Bashan confirmed Elfabrio was approved by the FDA's Rare Disease Division. Executive Eyal Rubin explained that since Protalix sells to its Italian partner Chiesi, the transaction is not directly subject to U.S. tariffs. Rubin also stated that, to their knowledge, Chiesi has not planned a price increase in response to potential tariffs, though this is Chiesi's decision.